Search Result

Results for "

Acy952 hdac Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HDAC (416) Adenosine Receptor (8) Akt (1) Aminopeptidase (1) AMPK (1) Amyloid-β (3) Anaplastic lymphoma kinase (ALK) (1) Angiotensin-converting Enzyme (ACE) (1) Apoptosis (129) Autophagy (40) Bcl-2 Family (2) Bcr-Abl (1) Beta-lactamase (5) c-Met/HGFR (2) Calcium Channel (1) Caspase (4) CCR (1) CDK (6) Cholinesterase (ChE) (5) COX (1) Cytochrome P450 (2) DNA/RNA Synthesis (4) Drug-Linker Conjugates for ADC (2) EBV (1) EGFR (1) Endogenous Metabolite (14) Epigenetic Reader Domain (3) Epoxide Hydrolase (1) Estrogen Receptor/ERR (1) Ferroptosis (1) FGFR (1) Filovirus (2) FLT3 (2) Fluorescent Dye (2) Fungal (3) G Protein-coupled Receptor Kinase (GRK) (1) G-quadruplex (1) Guanylate Cyclase (1) HIF/HIF Prolyl-Hydroxylase (2) Histone Acetyltransferase (4) Histone Demethylase (5) Histone Methyltransferase (3) HIV (17) HPV (2) HSP (5) iGluR (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Influenza Virus (1) Interleukin Related (5) Isotope-Labeled Compounds (8) JAK (5) Keap1-Nrf2 (1) MDM-2/p53 (3) Microtubule/Tubulin (8) Mitochondrial Metabolism (1) Mitophagy (14) MMP (1) Monoamine Oxidase (3) mTOR (5) MyD88 (1) NAMPT (2) Necroptosis (1) NF-κB (4) Notch (10) Organoid (3) Oxidative Phosphorylation (1) PAK (1) Parasite (8) PARP (3) Phosphatase (1) Phosphodiesterase (PDE) (6) PI3K (8) Pim (1) PKD (1) Potassium Channel (1) PROTACs (14) Proteasome (1) Reactive Oxygen Species (5) REV-ERB (1) SHP2 (1) Sirtuin (1) Small Interfering RNA (siRNA) (33) Sodium Channel (1) Tau Protein (1) TNF Receptor (4) Toll-like Receptor (TLR) (1) Topoisomerase (5) Tyrosinase (1) VD/VDR (1) VEGFR (2) Virus Protease (5)
By Research Areas:	Cancer (364) Cardiovascular Disease (7) Endocrinology (2) Infection (24) Inflammation/Immunology (26) Metabolic Disease (9) Neurological Disease (47)
Click Chemistry:	Alkynes (7)

478

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Targets Recommended: HDAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-150859

HDAC ligand-1

HDAC Cancer

HDAC ligand-1 is a HDAC ligand that can be used to synthesize PROTAC HDAC degraders .

HDAC ligand-1	HDAC	Cancer
HDAC ligand-1 is a *HDAC* ligand that can be used to synthesize PROTAC HDAC degraders .

HY-162086

HDAC-IN-68	HDAC	Cancer
HDAC-IN-68 (Compound 29) is a potent HDAC inhibitor that disrupts microtubule structure and inhibits tumor growth. HDAC-IN-68 significantly inhibits class I HDACs (HDAC1, HDAC2, HDAC3) with IC₅₀ values of 5.1, 11.5 and 8.8 nM, respectively .

HY-144102

HDAC-IN-29

HDAC Cancer

HDAC-IN-29 (compound 13b) is a potent pan-HDAC inhibitor. HDAC-IN-29 shows antitumor activity .

HDAC-IN-29	HDAC	Cancer
HDAC-IN-29 (compound 13b) is a potent pan-HDAC inhibitor. HDAC-IN-29 shows antitumor activity .

HY-157152

HDAC-IN-65	HDAC	Cancer
HDAC-IN-65 ( compound 6) is a selective histone deacetylase (HDAC) inhibitor with IC₅₀ value of 2.5μM. HDAC-IN-65 is a prodrug with very good bioreductive properties .

HY-149529

HDAC8-IN-5

HDAC Cancer

HDAC8-IN-5 (Compound 6a) is a HDAC8 inhibitor (IC₅₀: 28 nM). HDAC8-IN-5 can be used for cancer research .

HDAC8-IN-5	HDAC	Cancer
HDAC8-IN-5 (Compound 6a) is a *HDAC8* inhibitor (IC₅₀: 28 nM). HDAC8-IN-5 can be used for cancer research .

HY-163430

HDAC-IN-71	HDAC Apoptosis	Cancer
HDAC-IN-71 (Compound 17q) is a potent *HDAC* inhibitor with IC₅₀ values of 12.6, 14.1, 20, 3, and 72 nM for HDAC1, HDAC2, HDAC3, HDAC6, and HDAC10, respectively. HDAC-IN-71 induces apoptosis and can be used in cancer research .

HY-151897

HDAC-IN-49	HDAC	Cancer
HDAC-IN-49 is a potent unselective *HDAC* (HDAC) inhibitor with IC₅₀s of 13 nM, 14 nM, 21 nM, 1880 nM, and 10 nM for HDAC1, HDAC2, HDAC3, HDAC4, and HDAC6. HDAC-IN-49 demonstrates prominent antileukemic activity with low cytotoxic activity toward healthy cells .

HY-147934

HDAC8-IN-3	HDAC Apoptosis	Cancer
HDAC8-IN-3 (compound P19) is a potent *HDAC8* inhibitor with IC₅₀ value of 9.3 μM and produces thermal stabilization. HDAC8-IN-3 has cytotoxicity and induces apoptosis in leukemic cell lines .

HY-149284

JAK/HDAC-IN-3

JAK HDAC Cancer

JAK/HDAC-IN-3 (13a) is a dual JAK and HDAC inhibitor, with IC₅₀ values of 25.36 nM, 0.2 μM and 0.43 μM for JAK2, HDAC and HDAC1, respectively .

*JAK/HDAC-IN-3*	JAK HDAC	Cancer
JAK/HDAC-IN-3 (13a) is a dual JAK and *HDAC* inhibitor, with IC₅₀ values of 25.36 nM, 0.2 μM and 0.43 μM for JAK2, HDAC and HDAC1, respectively .

HY-150577

HDAC-IN-45	HDAC	Cancer
HDAC-IN-45 (Compound 14) is a small molecule *HDAC* inhibitor and has anticancer activity, also can forms a hydrogen bond with residue Y303. HDAC-IN-45 (Compound 14) has substantial inhibitory effects towards HDAC1, 2 and 3 isoforms with IC₅₀ values of 0.108, 0.585 and 0.563 μM respectively .

HY-149239

*Topo II/HDAC-IN-2*	Topoisomerase HDAC Apoptosis	Cancer
Topo II/HDAC-IN-2 (8d) exhibits excellent dual inhibitory activities against Topo II and *HDAC. Topo II/HDAC*-IN-2 (8d) induces apoptosis .

HY-149238

*Topo II/HDAC-IN-1*	Topoisomerase HDAC Apoptosis	Cancer
Topo II/HDAC-IN-1 (7d) exhibits excellent dual inhibitory activities against Topo II and *HDAC. Topo II/HDAC*-IN-1 (8d) induces apoptosis .

HY-157215

HDAC-IN-66

HDAC Cancer

HDAC-IN-66 (compound 2F) is a selective HDAC inhibitor and Pomalidomide (HY-10984) derivative that potently inhibits hematological tumor cells .

HDAC-IN-66	HDAC	Cancer
HDAC-IN-66 (compound 2F) is a selective *HDAC* inhibitor and Pomalidomide (HY-10984) derivative that potently inhibits hematological tumor cells .

HY-157490

*PARP/HDAC-IN-1*	PARP HDAC	Cancer
PARP/HDAC-IN-1 (compound B102) is a potent dual inhibitor of PARP and *HDAC. PARP/HDAC-IN-1 inhibits PARP1, PARP2* and *HDAC1* with IC₅₀s of 19.01, 2.13, 1690 nM, respectively .

HY-145851

*Top/HDAC-IN-1*	HDAC Topoisomerase Apoptosis	Cancer
Top/HDAC-IN-1 (Compound 29b) is a *topoisomerase/HDAC* dual inhibitor with IC₅₀s of 18, 230, 790, 87, and 5250 nM for HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8, respectively. Top/HDAC-IN-1 exhibits potent antitumor activities against the HCT116 cell line with the IC₅₀ of 180 nM. Top/HDAC-IN-1 efficiently induces apoptosis with G2 cell cycle arrest in HCT116 cells .

HY-149208

HDAC-IN-53	HDAC Apoptosis	Cancer
HDAC-IN-53 is an orally active, and selective *HDAC1-3* inhibitor with IC₅₀ values of 47 nM, 125 nM, and 450 nM, respectively. HDAC-IN-53 does not inhibit class II HDACs (HDAC4, 5, 6, 7, 9; IC₅₀>10 μM). HDAC-IN-53 induces caspase-dependent apoptosis. HDAC-IN-53 significantly inhibits the growth of human tumor xenografts in nude mice and murine tumor growth in immune-competent mice bearing MC38 colon cancer .

HY-149819

*CDK/HDAC-IN-3*	HDAC CDK	Cancer
CDK/HDAC-IN-3 is an orally active HDACs/CDKs dual inhibitor. CDK/HDAC-IN-3 has potent and selective inhibition of CDK9, CDK12, CDK13, HDAC1, HDAC2 and HDAC3 with IC₅₀ values of 98.32 nM, 98.85 nM, 100 nM, 62.12 nM, 93.28nM and 82.87 nM. CDK/HDAC-IN-3 can be used for the acute myeloid leukemia (AML) .

HY-154855

HDAC-IN-56	HDAC	Cancer
HDAC-IN-56 ((S)-17b) is an orally active class I histone deacetylase (HDAC) inhibitor with IC₅₀ values of 56.0 ± 6.0, 90.0 ± 5.9, 422.2 ± 105.1, >10000 nM for HDAC1, HDAC2, HDAC3, and HDAC4-11, respectively. HDAC-IN-56 has potent inhibitory activity while strongly increasing intracellular levels of acetylhistone H3 and P21 and effectively inducing G1 cell cycle arrest and apoptosis.HDAC-IN-56 has antitumor activity .

HY-142706

*MAO A/HDAC-IN-1*	Monoamine Oxidase HDAC	Cancer
MAO A/HDAC-IN-1 is a dual?inhibitor?of monoamine oxidase A (MAO A) and *HDAC. MAO A/HDAC-IN-1 can be used for glioma research . MAO A/HDAC*-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-161350

*ALK/HDAC-IN-1*	Anaplastic lymphoma kinase (ALK) HDAC	Cancer
ALK/HDAC-IN-1 is a dual inhibitor for ALK and HADC6, with IC₅₀s of 16 nM and 1.03 μM, respectively. ALK/HDAC-IN-1 exhibits antitumor activity .

HY-156094

*JMJD3/HDAC-IN-1*	HDAC Histone Demethylase Apoptosis	Cancer
JMJD3/HDAC-IN-1 (compound A5b) is a dual inhibitor targeting Jumonji domain-containing protein demethylase 3 (JMJD3) and histone deacetylase (HADC1, IC₅₀=16 nM). JMJD3/HDAC-IN-1 promotes hypermethylation of histone H3K27 and hyperacetylation of H3K9, and also cleaves caspase-7 and PARP to induce apoptosis. JMJD3/HDAC-IN-1 effectively inhibits cancer cell cloning, migration, and invasion .

HY-151896

HDAC6-IN-14

HDAC Cancer

HDAC6-IN-14 is a highly selective HDAC6 (HDAC) inhibitor with an IC₅₀ of 42 nM. HDAC6-IN-14 displays >100-fold selectivity over HDAC1/HDAC2/HDAC3/HDAC4 .

HDAC6-IN-14	HDAC	Cancer
HDAC6-IN-14 is a highly selective *HDAC6* (HDAC) inhibitor with an IC₅₀ of 42 nM. HDAC6-IN-14 displays >100-fold selectivity over HDAC1/HDAC2/HDAC3/HDAC4 .

HY-162377

HDAC-IN-70	HDAC Apoptosis Necroptosis	Cancer
HDAC-IN-70 (compound 4c) is *HDAC6* inhibitor with the IC₅₀ values of 64.13 nM, 166 nM, 618 nM and 253 nM for HDAC6, HDAC1, HDAC2 and HDAC4, respectively. HDAC-IN-70 induces cell cycle arrest, apoptosis and necrotic. HDAC-IN-70 can be used for study of leukemia .

HY-152174

HDAC-IN-52	HDAC	Cancer
HDAC-IN-52 is a pyridine-containing *HDAC* inhibitor, with IC₅₀s of 0.189, 0.227, 0.440 and 0.446 μM for *HDAC1, HDAC2, HDAC3, and HDAC10, respectively. HDAC*-IN-52 can be used for the research of cancer .

HY-147731

HDAC6-IN-9	HDAC	Cancer
HDAC6-IN-9 (compound 12c) is a potent and selective *HDAC6* inhibitor with IC₅₀ values of 11.8, 15.2, 4.2, 139.6, 21.3 nM for HDAC1,HDAC3, HDAC6, HDAC8, HDAC10, respectively. HDAC6-IN-9 shows anti-proliferative activities .

HY-146153

HDAC-IN-40	HDAC	Cancer
HDAC-IN-40 is a potent alkoxyamide-based *HDAC* inhibitor with K_i values of 60 nM and 30 nM for *HDAC2* and *HDAC6, respectively. HDAC*-IN-40 had antitumor effects .

HY-161304

HDAC6-IN-33	HDAC	Cancer
HDAC6-IN-33 (compound 6) is a selective and irreversible *HDAC6* inhibitor with an IC₅₀ of 193 nM. HDAC6-IN-33 shows no activity against HDAC1-4. HDAC6-IN-33 is a tight-binding HDAC6 inhibitor capable of inhibiting HDAC6 via a two-step slow-binding mechanism .

HY-152173

HDAC-IN-51	HDAC Apoptosis Bcl-2 Family CDK	Cancer
HDAC-IN-51 is a potent histone deacetylase (HDAC) inhibitor with IC₅₀ values of 0.32, 0.353, 0.431, 0.515, and 85.4 μM for HDAC10, HDAC1, HDAC2, HDAC3 and HDAC11, respectively. HDAC-IN-51 induces cell cycle arrest and apoptosis, modulating cell cycle-/apoptosis-related miRNAs expression. HDAC-IN-51 can be used in research of cancer .

HY-145688

HDAC-IN-33	HDAC	Cancer
HDAC-IN-33 is a potent *HDAC* inhibitor with IC₅₀s of 24, 46, and 47 nM for HDAC1, HDAC2 and HDAC6, respectively. HDAC-IN-33 possesses potent antiproliferation activities against tumor cells. HDAC-IN-33 shows potent antitumor efficacy in vivo That trigger antitumor immunity .

HY-149946

HDAC-IN-57	HDAC Apoptosis Histone Demethylase
HDAC-IN-57 is an orally active inhibitor of histone deacetylases (HDAC), with IC₅₀s of 2.07 nM, 4.71 nM, 2.4 nM and 107 nM for HDAC1, HDAC2, HDAC6, HDAC8, respectively. HDAC-IN-57 can inhibits LSD1, with IC₅₀ of 1.34 μΜ. HDAC-IN-57 induces apoptosis, and has anti-tumor activity .

HY-149859

HDAC-IN-58	HDAC	Neurological Disease
HDAC-IN-58 is a *HDAC* inhibitor. HDAC-IN-58 has HDAC6-specific inhibition activity with an IC₅₀ value of 2.06 nM. HDAC-IN-58 can be used for the research of chronic diseases, including neurodegenerative and psychiatric conditions .

HY-163290

HDAC-MB	Fluorescent Dye Monoamine Oxidase	Cancer
HDAC-MB a probe that is activated by HDAC6 and can detect and eliminate glioma cells through activation by HDAC6. HDAC-MB reveals antimetastatic and antiproliferative properties, inhibits glioma invasion and induces cellular apoptosis .

HY-153583

HDAC8-IN-4

HDAC Cancer

HDAC8-IN-4 is a selective inhibitor of HDAC8. HDAC8-IN-4 inhibits HDAC8 and HDAC3 with IC₅₀s of 0.15 and 12 μM .

HDAC8-IN-4	HDAC	Cancer
HDAC8-IN-4 is a selective inhibitor of *HDAC8. HDAC8-IN-4 inhibits HDAC8 and HDAC3 with IC₅₀*s of 0.15 and 12 μM .

HY-157385

HDAC-IN-67	HDAC Apoptosis	Cancer
HDAC-IN-67 (compound 27f) is an *HDAC* inhibitor against HDAC1 and HDAC6, with IC₅₀ values of 22 nM and 8 nM, respectively. HDAC-IN-67 inhibits cell proliferation and induces cell apoptosis. HDAC-IN-67 exhibits antitumor activity .

HY-145687

HDAC-IN-32	HDAC	Cancer
HDAC-IN-32 is a potent *HDAC* inhibitor with IC₅₀s of 5.2, 11, and 28 nM for HDAC1, HDAC2 and HDAC6, respectively. HDAC-IN-32 possesses potent antiproliferation activities against tumor cells. HDAC-IN-32 shows potent antitumor efficacy in vivo That trigger antitumor immunity .

HY-149372

HDAC6-IN-17	HDAC	Cancer
HDAC6-IN-17 (compound 5b) is a potent *HDAC6* inhibitor with IC₅₀ values of 150 nM, 1400 nM, and 2300 nM for HDAC6, HDAC8, and HDAC4, respectively. HDAC6-IN-17 has cytotoxic activity on human cancer cell lines. HDAC6-IN-17 can be used in research of cancer .

HY-144293

HDAC-IN-31	Apoptosis HDAC	Cancer
HDAC-IN-31 is a potent, selective and orally active *HDAC* inhibitor with IC₅₀s of 84.90, 168.0, 442.7, >10000 nM for HDAC1, HDAC2, HDAC3, HDAC8, respectively. HDAC-IN-31 induces apoptosis and cell cycle arrests at G2/M phase. HDAC-IN-31 shows good antitumor efficacy. HDAC-IN-31 has the potential for the research of diffuse large B-cell lymphoma .

HY-157314

HDAC6-IN-27	HDAC Parasite	Infection
HDAC6-IN-27 (compound 8C) is a *HDAC* inhibitor with IC₅₀ vales of 15.9 nM 136.5 nM and 6180.2 nM for HDAC6, HDAC8 and HDAC1, respectively. HDAC6-IN-27 shows potent antiparasitic effects .

HY-144292

HDAC-IN-30	HDAC	Cancer
HDAC-IN-30 is a novel multi-target *HDAC* inhibitor, including *HDAC1* (IC₅₀=13.4 nM),HDAC2 (IC₅₀=28.0 nM), *HDAC3* (IC₅₀=9.18 nM), *HDAC6* (IC₅₀=42.7 nM), *HDAC8* (IC₅₀=131 nM). HDAC-IN-30 exhibits potent antitumor efficacy .

HY-147840

HDAC-IN-41	HDAC	Cancer
HDAC-IN-41 (Compound 7c) is a selective, orally active class I *HDAC* inhibitor with IC₅₀ values of 0.62, 1.46 and 0.62 μM against HDAC1, HDAC2 and HDAC3, respectively. HDAC-IN-41 shows NO releasing activity .

HY-151443

HDAC-IN-47	HDAC	Cancer
HDAC-IN-47 is an orally active inhibitor of histone deacetylase (HDAC), with IC₅₀s of 19.75 nM (HDAC1), 5.63 nM (HDAC2), 40.27 nM (HDAC3), 57.8 nM (HDAC2), 302.73 nM (HDAC8), respectively. HDAC-IN-47 inhibits autophagy and induces apoptosis via the Bax/Bcl-2 and caspase-3 pathways. HDAC-IN-47 arrests cell cycle at G2/M phase, and shows anti-tumor efficacy in vivo .

HY-146750

HDAC-IN-37	HDAC Apoptosis	Cancer
HDAC-IN-37 is a potent *HDAC* inhibitor with IC₅₀s of 0.0551 μM, 1.24 μM, 0.948 μM and 34.2 μM for *HDAC1, HDAC3, HDAC8* and *HDAC6, respectively. HDAC-IN-37 induces histone acetylation in a slow-off manner. HDAC-IN-37 prevents cell transition from G1 phase to S phase and induces early cell apoptosis* .

HY-152235

HDAC6-IN-15	HDAC	Neurological Disease Cancer
HDAC6-IN-15 is a selective histone deacetylase 6 (HDAC6) inhibitor. HDAC6-IN-15 has potent inhibitory activity for HDAC6 with IC₅₀ value of 38.2 nM. HDAC6-IN-15 can be used for the research of cancer and neurodegenerative diseases .

HY-161154

HDAC3-IN-3

HDAC Cancer

HDAC3-IN-3 (compound 31) is a potent HDAC3 inhibitor. HDAC3-IN-3 has the potential for the research of cancer .

HDAC3-IN-3	HDAC	Cancer
HDAC3-IN-3 (compound 31) is a potent *HDAC3* inhibitor. HDAC3-IN-3 has the potential for the research of cancer .

HY-150595

HDAC6-IN-10	HDAC Microtubule/Tubulin	Cancer
HDAC6-IN-10 is a highly selective *HDAC6* inhibitor with the IC₅₀ of 0.73 nM. HDAC6-IN-10 has 144~10941-fold selectivity over other HDAC isoforms. HDAC6-IN-10 shows anti-proliferative activities against multiple myeloma cells .

HY-151261

HDAC6-IN-13	HDAC	Inflammation/Immunology
HDAC6-IN-13 (Compound 35m) is a potent, highly selective, orally active *HDAC6* inhibitor with an IC₅₀ of 0.019 μM. HDAC6-IN-13 also inhibits *HDAC1, HDAC2* and *HDAC3* with IC₅₀s of 1.53, 2.06 and 1.03 μM, respectively. HDAC6-IN-13 shows significant BBB permeability and anti-inflammatory activity .

HY-149497

HDAC6-IN-19	HDAC	Cancer
HDAC6-IN-19 (Compound 14g) is a *HDAC6* inhibitor (IC₅₀: 2.68 nM). HDAC6-IN-19 also inhibits HDAC1, HDAC2 and HDAC3 with IC₅₀s of 61.6 nM, 98.7 nM and 103 nM. HDAC6-IN-19 potently inhibits multiple cancer cell proliferation, including leukemia, colon cancer, melanoma, and breast cancer cell lines .

HY-146392

HDAC-IN-39	HDAC Microtubule/Tubulin Apoptosis	Cancer
HDAC-IN-39 (compound 16c) is a potent *HDAC* inhibitor, with IC₅₀ values of 1.07 μM (HDAC1), 1.47 μM (HDAC2), and 2.27 μM (HDAC3), respectively. HDAC-IN-39 also significantly inhibits microtubule polymerization. HDAC-IN-39 induces cell cycle arrest at the G2/M phase. HDAC-IN-39 displays promising anticancer activity against resistant cancer cells .

HY-151153

HDAC1-IN-5	HDAC Microtubule/Tubulin Caspase Apoptosis	Cancer
HDAC1-IN-5 is a potent *HDAC1* inhibitor with IC₅₀ values of 15 nM and 20 nM for HDAC1 and HDAC6, respectively. HDAC1-IN-5 can enhance the acetylation of histone H3 and α-tubulin, as well as promote the activation of caspase 3 in cancer cells, thereby inducing apoptosis. HDAC1-IN-5 induces chromatin damage by binding with DNA. HDAC1-IN-5 has strong inhibitory activity against tumor growth in xenograft mice .

HY-150722

HDAC6-IN-12	HDAC	Cancer
HDAC6-IN-12 (compound GZ) is a potent *HDAC6* inhibitor. HDAC6-IN-12 has anticancer activity through merges into DNA strands causing DNA damage. HDAC6-IN-12 can be used for cancer research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-15144

Trichostatin A Maximum Cited Publications 108 Publications Verification TSA	Structural Classification Classification of Application Fields Anti-aging Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields Cancer	Organoid HDAC
Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC₅₀ value of 1.8 nM for HDAC .

HY-N11692

9-Hydroxyoctadecanoic acid 9-Hydroxystearic acid; 9-HSA	Apocynaceae Structural Classification Strophanthus sarmentosus DC. Ketones, Aldehydes, Acids Source classification Plants	HDAC
9-Hydroxyoctadecanoic acid (9-HSA) is an *HDAC1* inhibitor that inhibits ∼66.4% HDAC1 enzymatic activity at 5 μM. 9-Hydroxyoctadecanoic acid shows anticancer activity .

HY-N0141

Parthenolide 20+ Cited Publications (-)-Parthenolide	Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Compositae Euchresta formosana (Hayata) Ohwi Disease Research Fields Cancer	NF-κB Autophagy Mitophagy Apoptosis
Parthenolide is a sesquiterpene lactone found in the medicinal herb Feverfew. Parthenolide exhibits anti-inflammatory activity by inhibiting NF-κB activation; also inhibits *HDAC1* protein without affecting other class I/II HDACs.

HY-N0071

Crotonoside Isoguanosine	Alkaloids Structural Classification Classification of Application Fields Croton tiglium Linn. Source classification Euphorbiaceae Plants Disease Research Fields Cancer	FLT3 HDAC
Crotonoside is isolated from Chinese medicinal herb, Croton. Crotonoside inhibits FLT3 and *HDAC3/6*, exhibits selective inhibition in acute myeloid leukemia (AML) cells. Crotonoside could be a promising new lead compound for the research of AML .

HY-N8707

Homobutein	Classification of Application Fields Source classification Plants Compositae Infection Chalcones Flavonoids Millettia pachyloba Drake Phenols Polyphenols Inflammation/Immunology Disease Research Fields Cancer	Parasite HDAC NF-κB
Homobutein a natural chalcones (can be found in many medicinal plants, fruits, vegetables, spices and nuts), is a potent *HDACs/NF-κB* dual inhibitor with IC₅₀s of 190 and 38 μM, respectively. Homobutein also a chelator of iron (II and III) cations, shows various activities, including anticancer, anti-inflammatory, antiparasite and antioxidation .

HY-10585A

Valproic acid sodium 30+ Cited Publications Sodium Valproate sodium	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (Sodium Valproate) sodium is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid sodium activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585

Valproic acid 30+ Cited Publications Dipropylacetic Acid	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (VPA) is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585B

Valproic acid (sodium)(2:1) VPA (sodium)(2:1); 2-Propylpentanoic Acid (sodium)(2:1)	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Cancer	HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (VPA) sodium (2:1) is an orally active *HDAC* inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits *HDAC1* (IC₅₀, 400 μM), and induces proteasomal degradation of *HDAC2. Valproic acid sodium (2:1) activates Notch1* signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-135476

Depudecin (-)-Depudecin	Structural Classification Natural Products Source classification Plants Brassicaceae Brassica campestris L.	HDAC
Depudecin ((-)-Depudecin) is a histone deacetylase (HDAC) inhibitor. Depudecin can be isolated from the fungus Alternaria brassicicola .

HY-N4315

Pomiferin NSC 5113	Classification of Application Fields Source classification Phenols Polyphenols Maclura pomifera (Raf.) Schneid. Plants Moraceae Disease Research Fields Cancer	HDAC mTOR
Pomiferin (NSC 5113) acts as an potential inhibitor of *HDAC, with an IC₅₀* of 1.05 μM, and also potently inhibits mTOR (IC₅₀, 6.2 µM).

HY-N6017

Bakkenolide A	Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Compositae Disease Research Fields Cancer Corethrodendron multijugum (Maximowicz) B. H. Choi & H. Ohashi	HDAC
Bakkenolide A is a natural product extracted from Petasites tricholobus. Bakkenolide A inhibits leukemia by regulation of HDAC3 and PI3K/Akt-related signaling pathways .

HY-P2698

1-Alaninechlamydocin	Natural Products Microorganisms Classification of Application Fields Source classification Disease Research Fields Cancer	HDAC Apoptosis
1-Alaninechlamydocin, a cyclic tetrapeptide, is a potent *HDAC* inhibitor (IC₅₀=6.4 nM). 1-Alaninechlamydocin induces G2/M cell cycle arrest and apoptosis in MIA PaCa-2 cells .

HY-N0931

Santacruzamate A 5+ Cited Publications CAY-10683	Alkaloids Structural Classification Microorganisms other families Classification of Application Fields Other Alkaloids Source classification Plants Disease Research Fields Cancer	HDAC Amyloid-β
Santacruzamate A (CAY-10683, STA) is a potent and selective HDAC2 inhibitor with an IC₅₀ of 119 pM. STA also exerts neuroprotective property against amyloid-β protein fragment 25–35. STA can be used for cancer and neurological disease research .

HY-N2345

Procyanidin B3	Flavonoids other families Classification of Application Fields Functional Molecules Source classification Research of Health Products Phenols Polyphenols Plants Biflavones Disease Research Fields Cancer	Histone Acetyltransferase
Procyanidin B3 is a natural product, acts as a specific HAT inhibitor, binds to the other site of p300 instead of the active site, selectively inhibits p300-mediated androgen receptor acetylation. Procyanidin B3 has no effect on HDAC or HMT (histone methyltransferase) .

HY-126566

Trichostatin C	Structural Classification Natural Products Microorganisms Source classification	Fungal HDAC Apoptosis
Trichostatin C is an inhibitor for histone deacetylase (HDAC), induces apoptosis and arrests cell cycle at G2/M phase, and exhibits anticancer activity against lung cancer and urothelial bladder cancer . Trichostatin C induces differentation of Friend leukemic cells . Trichostatin C exhibits antifungal activity .

HY-N2609

7,4'-Dihydroxyflavone 1 Publications Verification	Structural Classification Flavonoids Classification of Application Fields Flavones Leguminosae Source classification Phenols Polyphenols Plants Disease Research Fields Glycyrrhiza uralensis Fisch. Endocrinology	CCR NF-κB
7,4'-Dihydroxyflavone (7,4'-DHF) is a flavonoid, which can be isolated from Glycyrrhiza uralensis. 7,4'-Dihydroxyflavone is eotaxin/CCL11 inhibitor and CBR1 inhibitor (IC₅₀=0.28 μM). 7,4'-Dihydroxyflavone has the ability to consistently suppress eotaxin production and prevent dexamethasone (Dex)‐paradoxical adverse effects on eotaxin production . 7,4'-Dihydroxyflavone (7,4'-DHF) inhibits MUC5AC gene expression, mucus production and secretion via regulation of NF-κB, STAT6 and HDAC2.7,4'-Dihydroxyflavone (7,4'-DHF) decreases phorbol 12-myristate 13-acetate (PMA) stimulated NCI-H292 human airway epithelial cell MUC5AC gene expression and mucus production with IC₅₀ value of 1.4 µM .

HY-126052

Gnetol	Structural Classification Stilbenes Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Gnetaceae Plants Disease Research Fields Gnetum montanum Markgr.	COX Tyrosinase HDAC
Gnetol is a phenolic compound isolated from the root of Gnetum montanum . Gnetol potently inhibits COX-1 (IC₅₀ of 0.78 μM) and *HDAC. Gnetol is a potent tyrosinase* inhibitor with an IC₅₀ of 4.5 μM for murine tyrosinase and suppresses melanin biosynthesis. Gnetol has antioxidant, antiproliferative, anticancer and hepatoprotective activity. Gnetol also possesses concentration-dependent α-Amylase, α-glucosidase, and adipogenesis activities .

HY-W009732

Sinapinic acid 3 Publications Verification Sinapic acid	Monophenols other families Classification of Application Fields Simple Phenylpropanols Source classification Phenols Metabolic Disease Phenylpropanoids Plants Disease Research Fields	HDAC Angiotensin-converting Enzyme (ACE) Reactive Oxygen Species Apoptosis
Sinapinic acid (Sinapic acid) is a phenolic compound isolated from Hydnophytum formicarum Jack. Rhizome, acts as an inhibitor of *HDAC, with an IC₅₀* of 2.27 mM , and also inhibits ACE-I activity . Sinapinic acid posssess potent anti-tumor activity, induces apoptosis of tumor cells . Sinapinic acid shows antioxidant and antidiabetic activities . Sinapinic acid reduces total cholesterol, triglyceride, and HOMA-IR index, and also normalizes some serum parameters of antioxidative abilities and oxidative damage in ovariectomized rats .

HY-N7676

Marein	Cardiovascular Disease Flavonoids Chalcones other families Classification of Application Fields Neurological Disease Source classification Phenols Polyphenols Plants Disease Research Fields	AMPK HDAC
Marein has the neuroprotective effect due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway. Marein improves insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. Marein is a *HDAC* inhibitor with an IC₅₀ of 100 µM. Marein has beneficial antioxidative, antihypertensive, antihyperlipidemic and antidiabetic effects .

HY-13755

Sulforaphane 30+ Cited Publications	Structural Classification Natural Products other families Classification of Application Fields Source classification Plants Inflammation/Immunology Disease Research Fields	HDAC Keap1-Nrf2 Apoptosis Bcl-2 Family Caspase Reactive Oxygen Species
Sulforaphane is an orally active inducer of the Keap1/Nrf2/ARE pathway. Sulforaphane promotes the transcription of tumor-suppressing proteins and effectively inhibits the activity of *HDACs. Through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1* expression, Sulforaphane protects the heart. Sulforaphane suppresses high glucose-induced pancreatic cancer through AMPK-dependent signal transmission. Sulforaphane exhibits both anticancer and anti-inflammatory properties .

HY-B0809

Theophylline 5+ Cited Publications 1,3-Dimethylxanthine; Theo-24	Structural Classification Classification of Application Fields Source classification Plants Camellia sinensis (L.) O. Ktze. Endogenous metabolite Alkaloids Microorganisms Immune System Disorder Disease markers Disease Research Fields Cancer Theaceae	Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Endogenous Metabolite
Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research .

HY-B0809B

Theophylline sodium acetate 1,3-Dimethylxanthine sodium acetate; Theo-24 sodium acetate	Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor
Theophylline (1,3-Dimethylxanthine) sodium acetate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) sodium acetate inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) sodium acetate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) sodium acetate induces apoptosis. Theophylline (1,3-Dimethylxanthine) sodium acetate can be used for asthma and chronic obstructive pulmonary disease (COPD) research .

HY-B0809R

Theophylline (Standard) 1,3-Dimethylxanthine(Standard); Theo-24 (Standard)	Structural Classification Alkaloids Immune System Disorder Classification of Application Fields Source classification Disease markers Plants Camellia sinensis (L.) O. Ktze. Endogenous metabolite Disease Research Fields Cancer Theaceae	Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Endogenous Metabolite
Theophylline (Standard) is the analytical standard of Theophylline. This product is intended for research and analytical applications. Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research .

Species:	Human (5) Mouse (1)
Tag:	His (4) SUMO (2) Tag Free (1) GST (1)
Source:	Sf9 insect cells (3) E. coli (3)

Cat. No.	Compare	Product Name	Species	Source

HY-P75146

	HDAC4 Protein, Human (sf9) Histone deacetylase 4; HD4; hdac4; KIAA0288	Human	Sf9 insect cells
	The HDAC4 protein deacetylates core histones, thereby affecting transcription, cell cycle, and development. During muscle maturation, HDAC4 interacts with myocyte enhancer factors (MEF2A, MEF2C, and MEF2D). HDAC4 Protein, Human (sf9) is the recombinant human-derived HDAC4 protein, expressed by Sf9 insect cells , with tag free. The total length of HDAC4 Protein, Human (sf9) is 473 a.a., with molecular weight of ~51 kDa.

HY-P75144

	HDAC8 Protein, Mouse (sf9, His) Histone deacetylase 8; HD8; hdac8; hdacL1; CDA07	Mouse	Sf9 insect cells
	The HDAC8 protein is a histone deacetylase that removes acetyl groups from core histone lysine residues, contributing to epigenetic repression and affecting transcriptional regulation, cell cycle progression, and developmental events. It forms large multiprotein complexes and deacetylates SMC3, regulating the release of cohesin complexes. HDAC8 Protein, Mouse (sf9, His) is the recombinant mouse-derived HDAC8 protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of HDAC8 Protein, Mouse (sf9, His) is 377 a.a., with molecular weight of ~46 kDa.

HY-P75145

	HDAC8 Protein, Human (sf9, GST) Histone deacetylase 8; HD8; hdac8; hdacL1; CDA07	Human	Sf9 insect cells
	The HDAC8 protein is a histone deacetylase that has been shown to be critical for lysine deacetylation on core histones (H2A, H2B, H3, H4). This enzymatic activity initiates epigenetic repression that affects transcription, cell cycle, and developmental events. HDAC8 Protein, Human (sf9, GST) is the recombinant human-derived HDAC8 protein, expressed by Sf9 insect cells , with C-GST labeled tag. The total length of HDAC8 Protein, Human (sf9, GST) is 377 a.a., with molecular weight of ~68 kDa.

HY-P72223

	HDAC6 Protein, Human (His-SUMO) CPBHM; FLJ16239; HD 6; HD6; hdac 6; hdac6; hdac6_HUMAN; Histone deacetylase 6 HD6; ; Histone deacetylase 6; JM 21; JM21; KIAA0901; OTTHUMP00000032398; OTTHUMP00000197663; PPP1R90; Protein phosphatase 1 regulatory subunit 90	Human	E. coli
	The HDAC6 protein coordinates multiple functions, deacetylating histones and proteins such as tubulin and CTTN. Its role in epigenetic repression affects transcription, cell cycle, and development. HDAC6 Protein, Human (His-SUMO) is the recombinant human-derived HDAC6 protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag. The total length of HDAC6 Protein, Human (His-SUMO) is 488 a.a., with molecular weight of ~70.1 kDa.

HY-P72224

	HDAC6 Protein, Human (His) CPBHM; FLJ16239; HD 6; HD6; hdac 6; hdac6; hdac6_HUMAN; Histone deacetylase 6 HD6; ; Histone deacetylase 6; JM 21; JM21; KIAA0901; OTTHUMP00000032398; OTTHUMP00000197663; PPP1R90; Protein phosphatase 1 regulatory subunit 90	Human	E. coli
	The HDAC6 protein coordinates multiple functions, deacetylating histones and proteins such as tubulin and CTTN. Its role in epigenetic repression affects transcription, cell cycle, and development. HDAC6 Protein, Human (His) is the recombinant human-derived HDAC6 protein, expressed by E. coli , with N-6*His labeled tag. The total length of HDAC6 Protein, Human (His) is 352 a.a., with molecular weight of ~42.4 kDa.

HY-P72262

	*Histone deacetylase 1/HDAC1 Protein, Human (His-SUMO)* GON 10; HD1; hdac1; RPD3; RPD3L1	Human	E. coli
	Studies have confirmed that the histone deacetylase 1 (HDAC1) protein is a key enzyme that deacetylates lysine residues on core histones (H2A, H2B, H3, H4). This process establishes an epigenetic repressive signature that affects transcription, cell cycle, and developmental events. Histone deacetylase 1/HDAC1 Protein, Human (His-SUMO) is the recombinant human-derived Histone deacetylase 1/HDAC1 protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag. The total length of Histone deacetylase 1/HDAC1 Protein, Human (His-SUMO) is 482 a.a., with molecular weight of ~71-74 kDa.

Cat. No.	Product Name	Chemical Structure

HY-12163S

Entinostat-d4
Entinostat-d₄ is the deuterium labeled Entinostat[1]. Entinostat is an oral and selective class I HDAC inhibitor, with IC50s of 243 nM, 453 nM, and 248 nM for HDAC1, HDAC2, and HDAC3, respectively[2].

HY-10585AS1

Valproic acid-d14 sodium

Valproic acid-d₁₄ (sodium) is deuterium labeled Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-109015S

Tucidinostat-d4
Tucidinostat-d₄ is the deuterium labeled Tucidinostat. Tucidinostat is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC50s of 95, 160, 67 and 78 nM, respectively[1].

HY-10585AS

Valproic acid-d7 sodium

Valproic acid-d₇ (sodium) is the deuterium labeled Valproic acid (sodium salt). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S3

Valproic acid-d4 sodium

Valproic acid-d₄ (sodium) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-10585S4

Valproic acid-d4-1

Valproic acid-d₄-1 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S2

Valproic acid-d15

Valproic acid-d₁₅ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S

Valproic acid-d4

Valproic acid-d₄ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-10585S1

Valproic acid-d6

Valproic acid-d₆ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].

HY-B0809S

Theophylline-d6
Theophylline-d₆ is the deuterium labeled Theophylline. Theophylline is a nonselective phosphodiesterase (PDE) inhibitor, adenosine receptor blocker, and histone deacetylase (HDAC) activator.

HY-15654S

Phenylbutyrate-d11 sodium
Phenylbutyrate-d₁₁ (sodium) is deuterium labeled Sodium 4-phenylbutyrate. Sodium 4-phenylbutyrate (4-PBA sodium) is an inhibitor of HDAC and endoplasmic reticulum (ER) stress, used in cancer and infection research[1].

HY-A0281S

4-Phenylbutyric acid-d11
4-Phenylbutyric acid-d₁₁ is the deuterium labeled 4-Phenylbutyric acid. 4-Phenylbutyric acid (4-PBA) is an inhibitor of HDAC and endoplasmic reticulum (ER) stress, used in cancer and infection research.

HY-A0281S3

4-Phenylbutyric acid-d2
4-Phenylbutyric acid-d₂ is the deuterium labeled 4-Phenylbutyric acid[1]. 4-Phenylbutyric acid (4-PBA) is an inhibitor of HDAC and endoplasmic reticulum (ER) stress, used in cancer and infection research.

HY-A0281S2

4-Phenylbutyric acid-d5
4-Phenylbutyric acid-d₅ is the deuterium labeled 4-Phenylbutyric acid[1]. 4-Phenylbutyric acid (4-PBA) is an inhibitor of HDAC and endoplasmic reticulum (ER) stress, used in cancer and infection research[2][3][4].

HY-10528S

Tasquinimod-d3
Tasquinimod-d3 (ABR-215050-d3) is the deuterium labeled Tasquinimod (HY-10528). Tasquinimod is an oral antiangiogenic agent, which plays an important role in castration-resistant prostate cancer. Tasquinimod binds to the regulatory Zn ²⁺ binding domain of *HDAC4* with K_d of 10-30 nM. Tasquinimod also is a S100A9 inhibitor .

HY-10224S

Panobinostat-d4

Panobinostat-d₄ is the deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

HY-10224S1

Panobinostat-d4 hydrochloride

Panobinostat-d₄ (hydrochloride) is deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

Cat. No.	Product Name	Application	Reactivity

HY-P80149

HDAC1 Antibody	WB, IHC-P, ICC	Human, Mouse
HDAC1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 55 kDa, targeting to HDAC1. It can be used for WB,IHC-P,ICC assays with tag free, in the background of Human, Mouse.

HY-P80150

HDAC10 Antibody	WB, ICC, IP	Human
HDAC10 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 43 kDa, targeting to HDAC10. It can be used for WB,ICC,IP assays with tag free, in the background of Human.

HY-P80151

HDAC2 Antibody	WB, ICC/IF, IHC-P, IP, FC	Human, Mouse, Rat
HDAC2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 55 kDa, targeting to HDAC2. It can be used for WB,ICC/IF,IHC-P,IP,FC assays with tag free, in the background of Human, Mouse, Rat.

HY-P80152

HDAC3 Antibody	WB, ICC/IF, IHC-P, IP	Human, Mouse, Rat
HDAC3 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 49 kDa, targeting to HDAC3. It can be used for WB,ICC/IF,IHC-P,IP assays with tag free, in the background of Human, Mouse, Rat.

HY-P80153

HDAC4 Antibody	WB, ICC/IF	Human
HDAC4 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 120 kDa, targeting to HDAC4. It can be used for WB,ICC/IF assays with tag free, in the background of Human.

HY-P80154

HDAC6 Antibody	WB, ICC/IF, IHC-P, IP	Human
HDAC6 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 131 kDa, targeting to HDAC6. It can be used for WB,ICC/IF,IHC-P,IP assays with tag free, in the background of Human.

HY-P80700

HDAC4 Antibody (YA741) EC 3.5.1.98; HA6116; HD 4; HD4; hdac 4; hdac A; hdac4; hdac4_HUMAN; hdacA; Histone Deacetylase 4; Histone Deacetylase A; KIAA0288.	WB, IP	Human, Mouse, Rat, Monkey
HDAC4 Antibody (YA741) is a non-conjugated and Mouse origined monoclonal antibody about 119 kDa, targeting to HDAC4 (4A3). It can be used for WB,IP assays with tag free, in the background of Human, Mouse, Rat, Monkey.

HY-P80699

HDAC2 Antibody (YA742) hdac2; Histone deacetylase 2; HD2	WB, ICC/IF	Human, Mouse, Rat, Monkey
HDAC2 Antibody (YA742) is a non-conjugated and Mouse origined monoclonal antibody about 55 kDa, targeting to HDAC2 (2D9). It can be used for WB,ICC/IF assays with tag free, in the background of Human, Mouse, Rat, Monkey.

HY-P83139

HDAC11 Antibody (YA2884)

hdac11; HD11; Histone deacetylase 11
WB, IP Human
HY-P83401

HDAC7 Antibody (YA3146)

hdac7; hdac7A; Histone deacetylase 7; HD7; Histone deacetylase 7A; HD7a
WB, FC Human, Mouse, Rat

HY-P80701

HDAC6 Antibody (YA740) hdac6; KIAA0901; JM21; Histone deacetylase 6; HD6	WB	Human, Rat
HDAC6 Antibody (YA740) is a non-conjugated and Mouse origined monoclonal antibody about 131 kDa, targeting to HDAC6 (3B2). It can be used for WB assays with tag free, in the background of Human, Rat.

HY-P83249

HDAC8 Antibody (YA2994)

hdac8; hdacL1; CDA07; Histone deacetylase 8; HD8
WB, IP Human

HY-P83222

HDAC9 Antibody (YA2967) Histone deacetylase 9; HD9; Histone deacetylase 7B; HD7; HD7b; Histone deacetylase-related protein; MEF2-interacting transcription repressor MITR; hdac9; hdac7; hdac7B; HDRP; KIAA0744; MITR	WB, IHC-P	Human

HY-P80731

KDM1A Antibody (YA718) KDM1A; AOF2; KDM1; KIAA0601; LSD1; Lysine-specific histone demethylase 1A; BRAF35-hdac complex protein BHC110; Flavin-containing amine oxidase domain-containing protein 2	WB	Human, Mouse, Monkey
KDM1A Antibody (YA718) is a non-conjugated and Mouse origined monoclonal antibody about 93 kDa, targeting to KDM1A (1B2). It can be used for WB assays with tag free, in the background of Human, Mouse, Monkey.

HY-P81311

TBL1XR1 Antibody (YA1052) C21; DC42; F box like/WD repeat containing protein TBL1XR1; F-box-like/WD repeat-containing protein TBL1XR1; FLJ12894; IRA1; Nuclear receptor corepressor/hdac3 complex subunit; Nuclear receptor corepressor/hdac3 complex subunit TBLR1; TBL1 related protein 1; TBL1-related protein 1; TBL1R_HUMAN; TBL1XR1; Transducin (beta) like 1 X linked receptor 1; Transducin beta like 1X related protein 1; Transducin beta-like 1X-related protein 1.	WB, IHC-F, IHC-P, ICC/IF	Human, Mouse

HY-P81311A

TBL1XR1 Antibody (YA1053) C21; DC42; F box like/WD repeat containing protein TBL1XR1; F-box-like/WD repeat-containing protein TBL1XR1; FLJ12894; IRA1; Nuclear receptor corepressor/hdac3 complex subunit; Nuclear receptor corepressor/hdac3 complex subunit TBLR1; TBL1 related protein 1; TBL1-related protein 1; TBL1R_HUMAN; TBL1XR1; Transducin (beta) like 1 X linked receptor 1; Transducin beta like 1X related protein 1; Transducin beta-like 1X-related protein 1.	WB, IHC-P, ICC/IF	Human, Mouse, Rat

HY-P81339

TBLR1 Antibody (YA1084) C21; DC42; F box like/WD repeat containing protein TBL1XR1; F-box-like/WD repeat-containing protein TBL1XR1; FLJ12894; IRA1; Nuclear receptor corepressor/hdac3 complex subunit; Nuclear receptor corepressor/hdac3 complex subunit TBLR1; TBL1 related protein 1; TBL1-related protein 1; TBL1R_HUMAN; TBL1XR1; Transducin (beta) like 1 X linked receptor 1; Transducin beta like 1X related protein 1; Transducin beta-like 1X-related protein 1.	WB, IHC-P, ICC/IF	Human, Monkey

Cat. No.	Product Name		Classification

HY-142706

*MAO A/HDAC-IN-1*		Alkynes
MAO A/HDAC-IN-1 is a dual?inhibitor?of monoamine oxidase A (MAO A) and *HDAC. MAO A/HDAC-IN-1 can be used for glioma research . MAO A/HDAC*-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-163143

HDAC8-IN-6

Alkynes

HDAC8-IN-6 (compound 3) is a potent HDAC8 inhibitor with an IC₅₀ of 5.1 μM. HDAC8-IN-6 shows cytotoxicity .

HY-151872

HDAC-IN-48		Alkynes
HDAC-IN-48 is a potent *HDAC* inhibitor. HDAC-IN-48 is a hybrid molecule with great cytotoxic profile (GI₅₀~20 nM). HDAC-IN-48 consists of harmacophores of SAHA and CETZOLE molecules. HDAC-IN-48 induces ferroptosis and inhibits *HDAC* proteins . HDAC-IN-48 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-145259

HDAC6-IN-3		Alkynes
HDAC6-IN-3 (Compound 14), an antiprostate cancer agent, is a potent, orally active *HDAC6* inhibitor with IC₅₀s ranging from 0.02-1.54 μM for HDAC1/2/3/6/8/10. HDAC6-IN-3 is also an effective MAO-A (IC₅₀=0.79 μM) and LSD1 inhibitor . HDAC6-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-126943

SAHA-BPyne		Alkynes
SAHA-BPyne is an activity-based protein profiling (ABPP) probe for detecting HDAC activity, which covalently labels the proximal proteins through a photoactivation. SAHA-BPyne inhibits HDAC activity in HeLa nuclear lysate with an IC₅₀ of less than 5 μM .

HY-118783

2-Hexyl-4-pentynoic acid (±)-2-Hexyl-4-pentynoic acid		Alkynes
2-Hexyl-4-pentynoic acid ((±)-2-Hexyl-4-pentynoic acid), valproic acid (VPA) derivative, exhibits potential roles of *HDAC* inhibition (IC₅₀=13 μM) and HSP70 induction. Potent neuroprotective effects. 2-Hexyl-4-pentynoic acid causes histone hyperacetylation and protect against glutamate-induced excitotoxicity in cultured neurons . 2-Hexyl-4-pentynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10223

CUDC-101 5+ Cited Publications		Alkynes
CUDC-101 is a potent inhibitor of *HDAC, EGFR, and HER2* with IC₅₀s of 4.4, 2.4, and 15.7 nM, respectively. CUDC-101 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks